contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


carnegie-access-faron-pharmaceuticals-enters-into-convertible-bond-agreement

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Tieteellisiä foorumeita nämä, tietysti kaupalliset expot ohessa mutta mitään investor-matchmaking juttuja näissä ei ole fasilitoituna.  Ja nyt kun luin tarkemmin kysymyksesi niin kaupalliseen expoon rahalla, tiedestagelle tieteellä.

Tiedote tullut. Tässä kopio siitä Faron announces acceptance of bexmarilimab Phase II data for oral presentation at ASCO 2025 Faron Pharmaceuticals Ltd | Press Release | April 24, 2025 at 09:00:00 EEST Data from the BEXMAB study marks a significant milestone for next-generation cancer immunotherapies Turku, Finland, – Faron Pharmaceuticals Ltd. (AIM: FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that new Phase II data from its ongoing BEXMAB study evaluating bexmarilimab in high-risk myelodysplastic syndromes (HR-MDS) will be presented as a part of a Rapid Oral Abstract Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 30 May to 3 June 2025, in Chicago, Illinois, USA. The abstract, selected for oral communication, highlights the efficacy and tolerability of bexmarilimab, Faron’s novel humanized anti-Clever-1 antibody, with no dose-limiting toxicities during dose escalation, when used in combination with standard-of-care, azacitidine, treatment in patients with both treatment naïve (frontline) and relapsed/refractory (r/r) HR MDS patients. “We are thrilled to see bexmarilimab’s potential continuing to translate into clinical benefit for patients with this challenging hematologic malignancy,” said Dr. Petri Bono, Chief Medical Officer of Faron Pharmaceuticals. "The Phase II results build on our understanding of Clever-1 biology and bexmarilimab’s mode of action, and we believe this novel immunotherapy could offer a meaningful new treatment pathway for patients. The acceptance of our results for an oral presentation also represents an important company milestone, as it reflects the scientific interest we have generated, as recognized by the largest global oncology community — ASCO " Faron’s presence at ASCO 2025 reinforces the Company’s commitment to advancing science-driven novel immunotherapy solutions and to addressing unmet medical needs in oncology. The details of the oral presentation are as follows: Presentation title Efficacy of macrophage checkpoint Clever-1 inhibition with bexmarilimab plus azacitidine in myelodysplastic syndrome: Results from the ph1/2 BEXMAB study.  Session type and title Rapid Oral Abstract – Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant  Session date 30 May 2025  Time 1:00 PM - 2:30 PM CDT  Abstract no 6513  Presenter Dr. Naval Daver, MD Department of Leukemia, The University of Texas MD Anderson Cancer Center For more information, please contact: IR Partners, Finland  (Media)  Riina Tuominen  Kare Laukkanen +358 44 313 5005  riina.tuominen@irpartners.fi  +358 50 553 9535 / +44 7 469 766 223  kare.laukkanen@irpartners.fi  FINN Partners, US  (Media)  Alyssa Paldo +1 847 791-8085  alyssa.paldo@finnpartners.com  Cairn Financial Advisers LLP  (Nominated Adviser and Broker)  Sandy Jamieson, Jo Turner +44 (0) 207 213 0880  Sisu Partners Oy  (Certified Adviser on Nasdaq First North)  Juha Karttunen  Jukka Järvelä +358 (0)40 555 4727  +358 (0)50 553 8990 About BEXMAB  The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes. About bexmarilimab  Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care. About Faron Pharmaceuticals Ltd  Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

Vaikuttaa siltä, että nämä konffanäkyvyydet ovat merkittäviä promotilaisuuksia. Miten on- liikkuuko näissä esiintymismahdollisuuksissa raha vai onko se pelkästään tieteellinen kontribuutio (abstrakti), jolla stagelle pääsee?  Toinen mieltäni askarruttava kysymys on se, että tuleeko ennen Ascoa vielä uusi luenta ja sitä myöten uutta tietoa? Jos tulee niin onko kesäkuussakin vielä grand finale - eli elääkö nämä tulokset syvällisesti vielä n 2 kuukautta luoden arvoituksellisuutta tähän sijoituskeissiin?

Tässä on lainaus:  “…23. päivä, ja tällöin tiedämme esimerkiksi ASCO:n kannan, onko abstrakti hyväksytty ja millä laajuudella. Tämän tiedon saatuamme tulemme pitämään haastatteluja, joissa voimme vastata ainakin osaan teitä askarruttaneisiin kysymyksiin…”

Muistaakseni kyse oli jostain aikatauluista ym. ei niinkään tutkimusten tulosten sisällöistä.

Tässä on nyt vaan vielä se ongelma, että vain Amsterdamin 10.5 Zeidanin 13 minuutin keikan abstrakti ilmestyi julkisuuteen eikä sekään Faronin kautta.  Noista IWG2023 kriteereistä osa on yhä kehittelyn alla, mitä ne merkitsevät ja BEXMAB ohjannee osin sitä kehitystyötä Zeidanin kautta. CRh (selvästi vajaat verisoluvasteet) on sellainen epäselvä, AML:ssä FDA on jo sen hyväksynyt. HI eli verisolusrvojen parannus ja PR osittainen luuydinvaste näyttävät pidentävän elinaikaa ja erityisesti CR ja myös CRL. Ne kaikki ovat surrogaatteja eli kielivät eliniän pidentymisestä, sellaisia on katsottu, kun harkitaan AA-myyntilupaa varsinkin, kun ei ole elinaikatietoja saatavana. BEXMABissa alkaa olla. Elämänlaadun parantuminen liittyy noihin vasteisiin myös. Zeidan puhuu osin siitä, kun kertoo, miten Bex+aza vaikutti verensiirtojen vähenemisen eli kuinka oma verisolutuotanto on saatu stabiloitua. Daverin 6 minuutin rapid show ASCOssa 30.5 ei tule abstraktin osaltakaan näköjään kuukauteen julki ja siten tiedot ovat julkaisukiellossa eli haastattelut voisivat jäädä vähän vaisuiksi?

Erittäin hienoa! Nyt vain niitä P Koiviston lupaamia haastiksia Faronin toimista odottelemaan.

Faron Pharmaceuticals

Carnegie has published a new flash comment on Faron Pharmaceuticals following recent news flow.To access the full report and subscribe to future updates, visit https://www.carnegie.se/en/commissioned...

<div class="mfn-preamble"><p><strong>Carnegie has published a new flash comment on Faron Pharmaceuticals following recent news flow.</strong></p></div><div class="mfn-body"><p>To access the full report and subscribe to future updates, visit <a rel="noopener" href="https://www.carnegie.se/en/commissioned-research/faron/">https://www.carnegie.se/en/commissioned-research/faron/</a></p></div><div class="mfn-footer mfn-6fcd5977fc3f"><p><strong class="mfn-heading-1">Information</strong><br>This is a press release from Carnegie. For information about Carnegie commissioned research, see <a rel="noopener" href="https://www.carnegie.se/en/commissioned-research/">https://www.carnegie.se/en/commissioned-research/</a>, or contact our commissioned research team at <a rel="noopener" href="mailto:cr@carnegie.se">cr@carnegie.se</a>.</p></div><div class="mfn-footer mfn-contacts mfn-cb03f74a6f11"><p><strong class="mfn-heading-1">Contacts</strong><br>Visiting&nbsp;address: Regeringsgatan 56, Stockholm<br>Site: <a rel="noopener" href="http://www.carnegie.se/">http://www.carnegie.se</a><br>Telephone: +46 8-5886 88 00</p></div><div class="mfn-footer mfn-about mfn-f597257b14ff"><p><strong class="mfn-heading-1">About Us</strong><br>Carnegie is the leading and independent Nordic investment and private bank. Our operations within Corporate Finance, Securities and Research, Private Banking and Wealth Management are among the market leaders within their respective sectors. Together, they build an unbeatable combination of integrated knowledge, guiding our clients towards better business. Carnegie operates in six countries and has more than 800 employees.</p></div>

Carnegie Access: Faron Pharmaceuticals: Enters into convertible bond agreement

Privacy preferences